Private Insurance: Drug Screening For Opioid Users?

The opioid crisis has had a significant impact on the US healthcare system, with an economic burden estimated at $78.5 billion. Research shows that opioid abusers with private insurance generate high excess healthcare costs annually. This has led to an increase in drug testing in outpatient settings, with urine drug testing (UDT) being a common method to assess illicit drug use. From 2016 to 2020, private health plans recorded a substantial number of claims related to drug testing, indicating the growing focus on addressing opioid abuse and its associated costs. This raises the question of whether private insurance mandates drug screening when opioids are prescribed, and what impact this has on patient care and the overall healthcare system.

Financial impact of opioid crisis on US healthcare

The opioid crisis has had a significant financial impact on the US healthcare system. The economic cost of the opioid epidemic in the US was estimated at $1,021 billion in 2017, including the cost of opioid use disorder ($471 billion) and the cost of fatal opioid overdoses ($550 billion). The economic toll of the opioid crisis reached nearly $1.5 trillion in 2020, a 37% increase from 2017.

The opioid crisis has also disrupted the US labor force, with the epidemic accounting for an estimated 43% of the decline in men's labor force participation and 25% of the decline for women between 1999 and 2015. The crisis has resulted in labor supply disruptions, absenteeism, increased workplace accidents, and withdrawal from the labor force due to disability, incarceration, or death.

The financial impact of the opioid crisis on healthcare includes the costs of treatment for opioid use disorder, as well as the costs associated with the criminal justice system, lost productivity, reduced quality of life, and the value of statistical life lost. Additionally, the crisis has placed a significant burden on employers, who bear the costs of health insurance and workers' compensation for employees with opioid use disorder.

The Affordable Care Act (ACA) and the Mental Health Parity and Addiction Equity Act (MHPAEA) have played a role in expanding access to treatment for opioid use disorder. However, gaps in coverage still exist, and many individuals with private insurance do not have adequate coverage for drug use treatment.

Private health plans and drug testing

The opioid crisis has had a significant financial impact on the US healthcare system, with opioid abuse, overdose, and dependence costing the country an estimated $78.5 billion annually. Research shows that opioid abusers with private insurance generate higher healthcare costs than non-abusers, with an average excess cost of between $14,054 and $20,546 per year. This has led to an increase in drug testing by private health plans to address the issue.

From June 1, 2016, to February 29, 2020, three private health plans submitted a total of 2,004,230 claims for presumptive or definitive drug testing, with 1,532,581 of these claims being approved and paid. This data reflects a shift from hospital laboratories to independent laboratories for drug testing, with a focus on outpatient settings. The increase in drug testing by private health plans is likely due to the high cost of opioid abuse and the need to mitigate the financial and clinical burden on the healthcare system.

Urine drug testing (UDT) is commonly used in clinical and legal settings to detect illicit drug use. It is a reliable method for identifying opioid abuse and can help guide treatment decisions and prevent unwarranted opioid prescriptions. By implementing drug testing, private health plans can identify patients at risk of opioid abuse and provide appropriate interventions or referrals to substance abuse treatment programs. This can help reduce the number of opioid overdoses and the associated healthcare costs.

While drug testing can be a useful tool for private health plans, it is important to consider the ethical implications and ensure that patient privacy and consent are respected. Additionally, the cost of drug testing should be weighed against the potential benefits, as excessive testing may also contribute to the financial burden on the healthcare system. Overall, private health plans play a crucial role in addressing the opioid crisis through drug testing and implementing strategies to support patients at risk of opioid abuse.

Clinical and legal use of urine drug testing

Urine drug testing (UDT) is a critical component of pain management, allowing physicians to verify patient adherence to prescribed opioid regimens and detect the use of illicit or unauthorized licit drugs. Results of UDT can significantly impact therapeutic decisions and the level of trust between the physician and patient. However, the interpretation of UDT results can be challenging due to various factors, including metabolic conversion between drugs, genetic variations in drug metabolism, and the sensitivity and specificity of the analytical method used.

UDT is often employed as a monitoring tool for patients on chronic opioid therapy. It can help assess adherence to prescribed opioid regimens and detect misuse or abuse. UDT may be performed at baseline and periodically during ongoing monitoring, with the frequency determined by the patient's risk level. Definitive testing methods, such as gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), are generally considered more accurate than presumptive testing methods like immunoassays.

In the United States, the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 mandates that health insurers and group health plans provide equal coverage for mental and/or substance use treatment and services as they do for medical/surgical care. This includes coverage for medication-assisted treatment (MAT) and counseling for opioid addiction.

UDT is also used in various other contexts, such as employment screening, legal evidence in criminal investigations or court cases, drug treatment program monitoring, and sports drug testing. When used for employment screening, employers typically test for a range of drugs, including opioids, marijuana, and cocaine.

It is important to note that UDT results can be complex and influenced by factors such as an individual's metabolism and the methods used by different laboratories. Therefore, it is essential to consult with a healthcare provider to interpret the results accurately.

Impact of LBM on drug testing

Lean body mass (LBM) is a more accurate predictor of drug dosage than total body weight (TBW) or body surface area (BSA). LBM can be determined by a simple equation based on TBW and height or by bioelectrical impedance. The volume of distribution of relatively hydrophilic drugs correlates well with LBM, with correlation coefficients of up to 0.9. LBM can be used to accurately predict the loading dose required for these drugs to attain a target peak plasma concentration.

The implementation of a laboratory benefit management (LBM) program can positively address policy enforcement while reducing unnecessarily complex tests and limiting potential fraud, waste, and abuse by directing testing toward laboratories amenable to cost-efficient contractual savings. For definitive drug testing, the enforcement of the use of Healthcare Common Procedure Coding System codes and a move toward more cost-efficient tests (G0480), when clinically applicable, supported by clinical practice guidelines, or evidence-based medicine, is an approach to providing medical benefits while maintaining health costs.

Drug testing trends by POS in outpatient settings

The Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 requires health insurers and group health plans to provide the same level of benefits for mental and/or substance use treatment and services as they do for medical/surgical care. Despite this, many privately insured adults with drug use disorders in the United States do not have health care coverage for drug use treatment. This is a significant issue as it creates barriers to treatment and can impact an individual's overall health and well-being.

Drug Testing in Outpatient Settings

Drug testing is a common practice in outpatient settings, particularly for individuals struggling with substance use disorders. Outpatient treatment offers more freedom and flexibility than inpatient treatment, but it also comes with increased risks and temptations. Drug testing helps maintain accountability, resist temptation, and prove to loved ones that the individual is committed to their recovery. It is also an important tool for clinicians to determine the severity of the addiction and create an effective treatment plan.

Trends in Drug Testing by POS

There are several trends and variations in drug testing by Payor (POS) in outpatient settings. Here are some key trends to consider:

• Private Insurance Coverage: According to a study by Mojtabai et al. (2020), there was a modest increase in private insurance coverage for drug use treatment between 2005-2013 and 2014-2018. However, a significant proportion of privately insured adults with drug use disorders still lack coverage. This gap in coverage can create barriers to accessing necessary treatment.
• Medicaid Coverage: Medicaid is a major source of funding for mental health and substance use treatment, particularly for individuals with low incomes. The Affordable Care Act (ACA) has expanded Medicaid coverage, which has led to increased access to substance use treatment services.
• Variations by State: There are wide variations among states in the type and extent of substance use treatment services covered under insurance plans. This means that an individual's access to treatment can depend significantly on their location.
• Employer-Sponsored Insurance: Many individuals with employer-sponsored insurance may have coverage for substance use treatment. However, it is important to note that some large group commercial plans, known as "grandfathered" plans, are exempted from the essential health benefit requirement and may not cover substance use treatment.

Frequently asked questions